Shirley Ong
Distinguished in Primitive Neuroectodermal Tumor (PNET)

Dr. Shirley Ong

Hematology Oncology
UPMC
UPMC Hillman Cancer Center
5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
On Staff At
Offers Telehealth

Distinguished in Primitive Neuroectodermal Tumor (PNET)
UPMC
UPMC Hillman Cancer Center
5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shirley Ong, MD, specializes in hematology oncology and is board-certified in neurology by the American Board of Psychiatry and Neurology. She practices at UPMC Hillman Cancer Center and is affiliated with UPMC Shadyside and UPMC Presbyterian. Dr. Ong received her medical degree from the University of the East Ramon Magsaysay Memorial Medical Center and completed her residency at Saint Louis University School of Medicine, followed by a fellowship at the University of Texas MD Anderson Cancer Center.

Dr. Ong is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Her clinical research consists of co-authoring 14 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Psychiatry & Neurology in PA
Board Certifications
American Board Of Psychiatry And Neurology
Fellowships
University of Texas MD Anderson Cancer Center
Hospital Affiliations
Magee Womens Hospital Of Upmc Health System
Upmc Presbyterian Shadyside
Ohio State University State Health System
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

UPMC Hillman Cancer Center
5115 Centre Avenue, Hillman Cancer Center, Pittsburgh, PA 15232
Call: 412-756-3168

Additional Areas of Focus

Dr. Ong has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Suspended
Publish Date: December 12, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Biological
Study Drugs: PVSRIPO, Pembrolizumab
Study Phase: Phase 2
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Biological
Study Drugs: DNX-2401 Adeno-Associated Oncolytic Virus Delta-24 Vaccine, Pembrolizumab
Study Phase: Phase 2
View 5 Less Clinical Trials

14 Total Publications

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Journal: Nature medicine
Published: July 21, 2025
View All 14 Publications
Similar Doctors
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Sonikpreet Aulakh
Hematology Oncology | Hematology | Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Sonikpreet Aulakh
Hematology Oncology | Hematology | Oncology

West Virginia University Medical Corporation

1 Medical Ctr Dr, 
Morgantown, WV 
 (55.2 miles away)
304-598-4865
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sonikpreet Aulakh is a Hematologist Oncology specialist and a Hematologist in Morgantown, West Virginia. Dr. Aulakh is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Atypical Teratoid Rhabdoid Tumor (ATRT), Neuroepithelioma, Glioblastoma, and Gliosarcoma.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Leonard J. Appleman
Hematology Oncology | Oncology | Hematology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Leonard J. Appleman
Hematology Oncology | Oncology | Hematology

University Of Pittsburgh Physicians

5115 Centre Ave, 
Pittsburgh, PA 
 (0.6 miles away)
412-692-4724
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leonard Appleman is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Appleman is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, and Chromophobe Renal Cell Carcinoma.

Liza C. Villaruz
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Liza C. Villaruz
Hematology Oncology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Liza C. Villaruz
Hematology Oncology

UPMC Hillman Cancer Center

5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
 (0.1 miles away)
412-530-6683
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Liza C. Villaruz, MD, is board-certified in medical oncology and hematology at UPMC Hillman Cancer Center, and she specializes in lung cancer and thoracic malignancies. Dr. Villaruz is rated as an Elite provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC).

VIEW MORE PRIMITIVE NEUROECTODERMAL TUMOR (PNET) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ong's expertise for a condition
ConditionClose
    • Distinguished
    • Astrocytoma
      Dr. Ong is
      Distinguished
      . Learn about Astrocytoma.
      See more Astrocytoma experts
    • Atypical Teratoid Rhabdoid Tumor (ATRT)
      Dr. Ong is
      Distinguished
      . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
      See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
    • Brain Tumor
      Dr. Ong is
      Distinguished
      . Learn about Brain Tumor.
      See more Brain Tumor experts
    • Ependymoma
      Dr. Ong is
      Distinguished
      . Learn about Ependymoma.
      See more Ependymoma experts
    • Glioblastoma
      Dr. Ong is
      Distinguished
      . Learn about Glioblastoma.
      See more Glioblastoma experts
    • Glioma
      Dr. Ong is
      Distinguished
      . Learn about Glioma.
      See more Glioma experts
    View All 13 Distinguished Conditions
    • Advanced
    • Choroid Plexus Papilloma
      Dr. Ong is
      Advanced
      . Learn about Choroid Plexus Papilloma.
      See more Choroid Plexus Papilloma experts
    • Diffuse Midline Glioma H3 K27M-Mutant
      Dr. Ong is
      Advanced
      . Learn about Diffuse Midline Glioma H3 K27M-Mutant.
      See more Diffuse Midline Glioma H3 K27M-Mutant experts
    • Medulloblastoma
      Dr. Ong is
      Advanced
      . Learn about Medulloblastoma.
      See more Medulloblastoma experts
    • Experienced
    • Cerebral Ventricle Cancer
      Dr. Ong is
      Experienced
      . Learn about Cerebral Ventricle Cancer.
      See more Cerebral Ventricle Cancer experts
    • Dysembryoplastic Neuroepithelial Tumors (DNET)
      Dr. Ong is
      Experienced
      . Learn about Dysembryoplastic Neuroepithelial Tumors (DNET).
      See more Dysembryoplastic Neuroepithelial Tumors (DNET) experts
    • Legius Syndrome
      Dr. Ong is
      Experienced
      . Learn about Legius Syndrome.
      See more Legius Syndrome experts
    • Melanoma of the Eye
      Dr. Ong is
      Experienced
      . Learn about Melanoma of the Eye.
      See more Melanoma of the Eye experts
    • Neurofibromatosis
      Dr. Ong is
      Experienced
      . Learn about Neurofibromatosis.
      See more Neurofibromatosis experts
    • Pineoblastoma
      Dr. Ong is
      Experienced
      . Learn about Pineoblastoma.
      See more Pineoblastoma experts
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

        Close
        0 / 1000

        Please provide us with the below insurance information:

                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.